Citations

Clear

410 citation(s) found for "Shu, Yu".

Histologic Variants of Kaposi Sarcoma in the Gastrointestinal Tract
Zheng, Wei , Obeng, Rebecca C. , Lui, Shu, Cheng, Jerome , Alexiev, Borislav A. , Escobar, David , Liu, Xiuli , Navale, Pooja , Westerhoff, Maria , Xue, Yue , Graham, Rondell P. , Lui, Shu, Quigley, Brian M. , Krasinskas, Alyssa M. , Yang, Guangyu , Reid, Michelle D.

Mayo Clinic

American Journal of Surgical Pathology | August 16, 2022 | Volume: 46 | Issue: 11 | Pages: 1500-1506

10.1097/pas.0000000000001937 | PMID 35973011 Get It

Kaposi sarcoma (KS) can pose diagnostic challenges in biopsy specimens. Multiple histologic variants of cutaneous KS have been described; however, the histomorphologic spectrum of gastrointestinal (GI) KS has not been systematically studied. This large series comprehensively evaluated 46 cases of KS involving the GI tract and identified 7 histomorphologic variants, some that have not been previously described. Five of them are inconspicuous but have unique morphologic patterns, including lymphangioma/lymphangiectatic–like (n=17), mucosal hemorrhage/telangiectatic–like (n=17), mucosal inflammation–like (n=15), granulation tissue–like (n=13), and mucosal prolapse–like (n=4) variants. These variants can be easily misdiagnosed or misinterpreted on routine examination if KS is not considered, and if the immunohistochemical stain for human herpesvirus-8 is not performed. The other 2 morphologic variants present as spindle cell proliferations and are the GI stromal tumor–like (n=8) and inflammatory myofibroblastic tumor–like (n=2). These variants raise a broad differential diagnosis of spindle cell tumors of the GI tract and could pose diagnostic challenges. In summary, GI KS lesions exhibit variable, often unconventional histomorphologic patterns. KS should be included in the differential diagnosis even if features of conventional KS are not seen, particularly in limited biopsies in immunocompromised patients, such as those with human immunodeficiency virus infection. Although the clinical significance of these morphologic variants is yet to be determined, they are nonetheless important from a diagnostic standpoint. Misdiagnosis and delay in appropriate management can be avoided by recognizing the morphologic diversity of GI KS and appropriately utilizing the human herpesvirus-8 immunohistochemical stain.
Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data fromCALGB80405 (Alliance)/SWOG80405
Blarigan, Erin L. Van , Bainter, Tiffany M., Ng, Kimmie , Niedzwiecki, Donna , Giovannucci, Edward L. , Lenz, Heinz‐Josef , Polite, Blasé N. , Höchster, Howard S. , Goldberg, Richard M. , Blanke, Charles D. , Ciombor, Kristen K. , Meyerhardt, Jeffrey A. , Van Blarigan, Erin L , Lenz, Heinz-Josef , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Ma, Chao , Ou, Fang‐Shu , Venook, Alan P. , Mayer, Robert J. , O’Reilly, Eileen M.

Mayo Clinic

International Journal of Cancer | July 29, 2022 | Volume: 152 | Issue: 2 | Pages: 123-136

10.1002/ijc.34230 | PMID 35904874 Get It

AbstractData on diet and survival among people with metastatic colorectal cancer are limited. We examined dietary fat in relation to all‐cause mortality and cancer progression or death among 1149 people in the Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group (SWOG) 80405 trial who completed a food frequency questionnaire at initiation of treatment for advanced or metastatic colorectal cancer. We examined saturated, monounsaturated, total and specific types (n‐3, long‐chain n‐3 and n‐6) of polyunsaturated fat, animal and vegetable fats. We hypothesized higher vegetable fat intake would be associated with lower risk of all‐cause mortality and cancer progression. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI). Over median follow‐up of 6.1 years (interquartile range [IQR]: 5.3, 7.2 y), we observed 974 deaths and 1077 events of progression or death. Participants had a median age of 59 y; 41% were female and 86% identified as White. Moderate or higher vegetable fat was associated with lower risk of mortality and cancer progression or death (HRs comparing second, third and fourth to first quartile for all‐cause mortality: 0.74 [0.62, 0.90]; 0.75 [0.61, 0.91]; 0.79 [0.63, 1.00];Ptrend: .12; for cancer progression or death: 0.74 [0.62, 0.89]; 0.78 [0.64, 0.95]; 0.71 [0.57, 0.88];Ptrend: .01). No other fat type was associated with all‐cause mortality and cancer progression or death. Moderate or higher vegetable fat intake may be associated with lower risk of cancer progression or death among people with metastatic colorectal cancer.
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies
Jung, Audrey , Ahearn, Thomas U. , Behrens, Sabine , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Arndt, Volker , Aronson, Kristan J. , Brenner, Hermann , Eriksson, Mikael , Evans, D. Gareth , Hadjisavvas, Andreas , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute , Hoppe, Reiner , Howell, Anthony , Hunter, David J. , Kosma, Veli‐Matti , Lissowska, Jolanta , Loizidou, Maria A. , Mannermaa, Arto , Maurer, Tabea, Olsson, Håkan , Patel, Alpa V , Perou, Charles M. , Shibli, Rana , Stone, Jennifer , Vachon, Celine M. , Wang, Sophia , Wu, Anna H. , Yang, Xiaohong R. , Zheng, Wei , Easton, Douglas F. , Chatterjee, Nilanjan , García‐Closas, Montserrat , Chang‐Claude, Jenny , Olsson, Håkan , Jung, Audrey Y , Becher, Heiko , Brenner, Hermann , Canzian, Federico , Czene, Kamila , Eliassen, A Heather , Figueroa, Jonine D , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G , Guénel, Pascal , Hadjisavvas, Andreas , Håkansson, Niclas , Hall, Per N , Hüsing, Anika , Koutros, Stella , Kraft, Peter , Marchand, Loïc Le , Lissowska, Jolanta , Loizidou, Maria A , Mannermaa, Arto , Murphy, Rachel A , Olsson, Håkan , Patel, Alpa V , Perou, Charles M , Shu, Xiao-Ou , Southey, Melissa C , Stone, Jennifer , Tamimi, Rulla M , Vachon, Celine M. , Wolk, Alicja , Dunning, Alison M , Pharoah, Paul D P , Easton, Doug , Milne, Roger L , Schmidt, Marjanka K , García-Closas, Montserrat , Chang-Claude, Jenny , Behrens, Sabine , Evans, D Gareth , Arndt, Volker , Kapoor, Pooja Middha , Zheng, Wei , Eriksson, Mikael , Wang, Sophia S , Wang, Qin , Augustinsson, Annelie , Freeman, Laura E. Beane , Becher, Heiko , Canzian, Federico , Carey, Lisa A. , Czene, Kamila , Eliassen, A. Heather , Figueroa, Jonine D. , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G. , Guénel, Pascal , Hopper, John L. , Hüsing, Anika , Kaaks, Rudolf , Koutros, Stella , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Murphy, Rachel A. , Olshan, Andrew F. , Rennert, Gad , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Teras, Lauren R. , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Dunning, Alison M. , Pharoah, Paul D.P. , Milne, Roger L. , Schmidt, Marjanka K.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 20, 2022 | Volume: 114 | Issue: 12 | Pages: 1706-1719

10.1093/jnci/djac117 | PMID 35723569 Get It

AbstractBackgroundReproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear.MethodsAnalyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2–like, HER2-enriched–like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided.ResultsCompared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2–like, and HER2-enriched–like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like.ConclusionsThis large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction.
ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).
Li, Jing , Revzin, Alexander , Nelson, Garth D. , Ness, Andrew, Schuster, Carissa E., Jia, Jingquan, Wee, Wen , Ou, Fang‐Shu , Tran, Nguyen H. , Babiker, Hani M. , Dong, Haidong , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS4170-TPS4170

10.1200/jco.2022.40.16_suppl.tps4170 Get It

TPS4170 Background: IMbrave150 is the first study demonstrating the benefit of anti-PDL1 in the frontline treatment of aHCC, and established Atezo/Bev as a new 1st line standard for aHCC. There is currently limited evidence to guide subsequent therapy for aHCC patients progressing on Atezo/Bev. ACCRU-GI-2008 is designed to determine the benefit of continuing Atezo into 2nd line and the safety of Atezo plus a MKI in patients with aHCC who previously received Atezo/Bev. The study is being conducted across 12 centers in the United States (ClincalTrials.gov#: NCT05168163). Methods: This study utilizes a 2:1 randomized phase II design where eligible patients will receive either Atezo/MKI (experimental arm) or MKI alone (control). Patients will be stratified according to the MKI choice (cabozantinib or lenvatinib, per physician’s decision), etiology of HCC (viral vs. non-viral) and alpha-fetoprotein level ( < 400 vs. > = 400 ng/mL). The major eligibility criteria are histological/cytological diagnosis or clinical diagnosis of HCC per the AASLD or WASL 2018 guidelines, has advanced disease not amendable to curative treatment, previously received and progressed on Atezo/Bev, has received only 1 previous line of systemic therapy (2nd line only), ECOG PS 0-1, Child Pugh Class A, adequate organ reserves and RECIST v1.1 measurable disease; previous MKI for advanced disease is excluded. The primary endpoints are overall survival (OS) and progression free survival (PFS). A total sample size of 122, with 89 PFS events, we will have 80% power to detect an improvement in median PFS from 4 to 7 months, assuming a one-sided significance level of 0.05. With approximately 84 deaths, we will have 80% power to detect an improvement in median OS from 10 to 18 months, assuming a one-sided significance level of 0.05. The overall one-sided significance level, for the study, is 0.1. An OS interim analysis will be conducted at 89 PFS events. Secondary endpoints include objective response, duration of response, and adverse events. Archival tumor and serial blood samples will be collected to evaluate for potential prediction biomarkers and mechanisms of sensitivity/resistance. Baseline and on-treatment tumor biopsy specimens will also be collected from the initial 10 patients of each arm. The study is approved by the ethics committee and enrollment to the study will be underway by Q2/3 2022. Clinical trial information: NCT05168163.
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
Arai, Hiroyuki, Yang, Yan , Millstein, Joshua , Denda, Tadamichi , Innocenti, Federico , Doi, Ayako , Horie, Yoshiki , Umemoto, Kumiko , Izawa, Naoki , Wang, Jingyuan , Kawanishi, Natsuko , Zhang, Wu , Sunakawa, Yu , Lenz, Heinz‐Josef , Arai, Hiroyuki , Ou, Fang‐Shu , Takeda, Hiroyuki , Battaglin, Francesca , Jayachandran, Priya , Soni, Shivani , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 3586-3586

10.1200/jco.2022.40.16_suppl.3586 Get It

3586 Background: HSP90 mediated chaperoning is a well-conserved biological mechanism for stabilization and activation of kinases. More than 60% of human kinases including VEGFR, CRAF, CSF1R, and FGFR are target of HSP90 (client kinases), whereas EGFR is non-client. CDC37 is a specific co-chaperone determining selectivity of client kinases recognized by HSP90. We hypothesized that gene expression levels of CDC37 have predictive values for anti-angiogenic therapies in mCRC. Methods: The subjects of this study were mCRC patients treated with regorafenib (REGO, Japanese retrospective cohort) and those treated with bevacizumab (BEV) or cetuximab (CET) in combination with first-line chemotherapy (CALGB/SWOG 80405 trial cohort). CDC37 expression levels were measured using RNA isolated from FFPE samples by nCounter gene expression profiling (Nanostring) and HiSeq 2500 (Illumina) in the Japanese and CALGB/SWOG 80405 cohorts, respectively. Overall survival (OS) and progression-free survival (PFS) were compared between patients with high CDC37 expression ( CDC37-H) and those with low expression ( CDC37-L), grouped by median cutoff value in each cohort. Results: In total, 484 patients were included (50 treated with REGO, 227 treated with BEV, and 207 treated with CET). In REGO-treated patients, CDC37-H showed significantly better OS (median 11.3 vs 6.0 months, adjusted hazard ratio [HR] 0.24, 95% confidence interval [CI] 0.11-0.54, p <0.01) and PFS (median 3.5 vs 1.9 months, adjusted HR 0.51, 95% CI 0.28-0.94, p = 0.03) compared to CDC37-L. Similarly, in BEV-treated patients, CDC37-H showed significantly better PFS (median 13.5 vs 9.6 months, adjusted HR 0.59, 95% CI 0.43-0.79, p <0.01) and numerically better OS (median 34.1 vs 29.4 months, adjusted HR 0.81, 95% CI 0.60-1.11, p = 0.20) compared to CDC37-L. However, in CET-treated patients, CDC37-H and CDC37-L patients showed similar OS (median 33.7 vs 26.1 months, adjusted HR 1.00, 95% CI 0.73-1.38, p = 0.98) and PFS (median 11.3 vs 11.0 months, adjusted HR 1.08, 95% CI 0.81-1.45, p = 0.60). Significant interaction was observed between CDC37 expression and treatment in terms of PFS in the CALGB/SWOG 80405 cohort ( p = 0.01). Conclusions: Our results suggest patients with CDC37-dependent ( CDC37-H) tumors may derive more benefit from REGO and BEV both of which target HSP90 client kinases or signaling pathways, but not from CET which target HSP90 non-client kinase. Further validation studies are warranted to develop a novel personalized approach for targeted therapies based on CDC37 expression in mCRC patients. Support: U10CA180821, U10CA180888; Pfizer, Genentech; https://acknowledgments.alliancefound.org. ClinicalTrials.gov Identifier: NCT00265850.
Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.
Zhang, Wu, Millstein, Joshua , Yang, Yan , Innocenti, Federico , Arai, Hiroyuki, Algaze, Sandra, Deming, Dustin A. , Goldberg, Richard M. , Blanke, Charles D. , Kabbarah, Omar , Lenz, Heinz‐Josef , Ou, Fang‐Shu , Arai, Hiroyuki , Soni, Shivani , Mumenthaler, Shannon M. , Algaze, Sandra , Jayachandran, Priya , Bertagnolli, Monica M. , Niedzwiecki, Donna , Mayer, Robert J. , Venook, Alan P. , Battaglin, Francesca

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 3580-3580

10.1200/jco.2022.40.16_suppl.3580 Get It

3580 Background: Monoamine oxidases (MAOs), including MAOA and MAOB, are mitochondrial enzymes responsible for catalyzing monoamine oxidation. Increased expression of MAOs were found in several cancer types and high MAOB was associated with worse disease stage and poorer survival in CRC. Positive and negative correlations of MAOB expression with mesenchymal type and epithelial type gene expressions, respectively, have been reported. Hence, we investigated whether MAOB expression is predictive for targeted therapies in mCRC. Methods: 430 mCRC pts treated with either bevacizumab (BEV, n = 224) or cetuximab (CET, n = 206) in combination with first-line chemotherapy within the CALGB/SWOG 80405 trial were included in the analysis. MAOB RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). Overall survival (OS) and progression-free survival (PFS) were compared between groups of pts categorized by tertiles of MAOB expression into high (H), medium (M) and low (L). Hazard ratios (HR) and 95% confidence intervals (CI) were computed from multivariable Cox proportional hazards model, adjusting for age, sex, location, number of metastases, KRAS, MSI status, and treatment with FOLFOX or FOLFIRI. Sensitivity analyses were conducted after stratifying by sex. Logrank P-values describe differences without adjustment for patient characteristics. Results: In CET-treated pts, MAOB-L showed significantly longer OS (median 39.2 vs 30.9 vs 15.9 months, logrank P = 4.7E-05, L vs H (as reference) adjusted HR 0.42, 95% CI [0.27, 0.65]) and PFS (median 13.2 vs 11.8 vs 7.6 months, logrank P = 0.006, L vs H adjusted HR 0.59 [0.40, 0.88]) compared to MAOB-M and MAOB-H, respectively. Similar results were observed when evaluating MAOB expression as a continuous variable. In BEV-treated pts, no significant differences were observed when comparing MAOB expression tertiles; however, pts with lower MAOB expression had significantly better OS, but not PFS, when evaluating MAOB as a continuous variable (Cox LRT P = 0.015, covariate adjusted). In CET-treated pts, the effect of MAOB expression was observed in male but not female pts (OS: median 40.3 vs 30.9 vs 16.1 months by MAOB-L, M, H, respectively, logrank P = 6.8E-05, L vs H adjusted HR 0.33 [0.19, 0.59]; PFS: median 13.8 vs 12.6 vs 7.9 months, logrank P = 0.001, L vs H adjusted HR 0.46 [0.28, 0.79]). A significant interaction was observed between MAOB expression and treatment for OS ( P = 0.010) in males and females combined, but only in males ( P = 0.018) when stratified by sex. Conclusions: Our results suggest that pts with MAOB-L tumors may have greater benefit from CET-based treatment and that targeting MAOB may be a promising strategy to improve patient outcomes. Further validation studies are warranted to develop a novel personalized approach based on MAOB expression in mCRC pts. Clinical trial information: NCT00265850.
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).
Kohn, Christine G. , Ma, Chao , Chen, Yuan , Hollis, Bruce W. , Lenz, Heinz‐Josef , Blanke, Charles D. , Goldberg, Richard M. , Ng, Kimmie , Ou, Fang‐Shu , Larson, Nicholas B. , Zemla, Tyler , Niedzwiecki, Donna , Nixon, Andrew B. , Mayer, Robert J. , Venook, Alan P. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 3553-3553

10.1200/jco.2022.40.16_suppl.3553 Get It

3553 Background: Higher levels of plasma 25-hydroxyvitamin D [25(OH)D)] are associated with better outcomes in mCRC, but underlying biologic mechanisms are unknown. Key components of the VitD metabolic pathway include CYP27B1 (encodes 1-α-hydroxylase, converts 25(OH)D to active calcitriol), VitD receptor (VDR), and CYP24A1 (encodes 24-hydroxylase, degrades calcitriol and 25(OH)D into excreted metabolites). Since these factors may affect 25(OH)D levels and potentially mediate VitD activity in mCRC, we examined the relationship between tumoral gene expression (GEx) of CYP27B1, VDR, and CYP24A and pt outcome in a study nested in a randomized phase III trial of first-line chemotherapy plus biologics in mCRC pts, CALGB/SWOG 80405. Methods: We determined GEx of CYP27B1, VDR, and CYP24A1 by RNA sequencing (RNA-Seq) of archival tumor samples using the Illumina TruSeq platform. Primary endpoints were overall (OS) and progression-free survival (PFS). Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for prognostic and molecular characteristics. Results: 562 pts with RNA-Seq data were included. Pts with higher CYP27B1 expression (>median) were less likely to have BRAF wild type (WT) (79% vs 90%) compared to pts with lower expression (p=0.0007). Pts with higher VDR expression (>quartile 1 [Q1]) were younger (median age 59 vs 62 years; p=0.03), more likely to have left-sided (63% vs 46%; p=0.0005) and BRAF WT tumors (89% vs 70%; p<0.0001), and less likely to have RAS WT tumors (70% vs 80%; p=0.02) compared to pts with lower VDR. Pts with higher CYP24A1 expression (>median) were more likely to have left-sided tumors compared to pts with lower expression (63% vs 54%; p=0.03). On multivariable analysis, pts with higher CYP27B1 expression had significantly improved OS (HR 0.84; 95% CI, 0.75-0.93; p=0.002) and PFS (HR 0.89; 95% CI, 0.80-0.99; p=0.04). Higher VDR expression (up to Q1) was associated with significantly improved PFS (HR 0.69; 95% CI, 0.53-0.91; p=0.007) but not OS (HR 0.85; 95% CI, 0.66-1.09; p=0.20). Above Q1, this improvement attenuated. Higher CYP24A1 GEx was not associated with improved OS (HR 0.98; 95% CI, 0.88-1.08; p=0.66) or PFS (HR 0.98; 95% CI, 0.89-1.08; p=0.68). We found no significant interactions between GEx of CYP27B1, VDR, or CYP24A with baseline plasma 25(OH)D levels (p for interaction ≥0.10 for all). Conclusions: Our findings suggest an association between GEx of VitD pathway markers, particularly CYP27B1 and VDR, and survival in pts with mCRC, lending biologic plausibility to a role of VitD in CRC pathogenesis. Future studies are needed to confirm these findings and elucidate underlying mechanisms of action. Clinical trial information: NCT00265850 .
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab
Innocenti, Federico, Yazdani, Akram, Rashid, Naim, Qu, Xueping, Ou, Fang‐Shu , Buren, Scott Van, Bertagnolli, Monica M. , Kabbarah, Omar, Blanke, Charles David, Venook, Alan P. , Lenz, Heinz‐Josef , Vincent, Benjamin G , Venook, Alan P , Bertagnolli, Monica M , Ou, Fang-Shu , Kabbarah, Omar , Innocenti, Federico, Yazdani, Akram, Rashid, Naim, Qu, Xueping, Buren, Scott Van, Blanke, Charles David, Lenz, Heinz-Josef

Mayo Clinic

Clinical Cancer Research | April 14, 2022 | Volume: 28 | Issue: 8 | Pages: 1690-1700

10.1158/1078-0432.ccr-21-3202 | PMID 35176136 Get It

Abstract Purpose: CALGB/SWOG 80405 was a randomized phase III trial in first-line patients with metastatic colorectal cancer treated with bevacizumab, cetuximab, or both, plus chemotherapy. We tested the effect of tumor immune features on overall survival (OS). Experimental Design: Primary tumors (N = 554) were profiled by RNA sequencing. Immune signatures of macrophages, lymphocytes, TGFβ, IFNγ, wound healing, and cytotoxicity were measured. CIBERSORTx scores of naive and memory B cells, plasma cells, CD8+ T cells, resting and activated memory CD4+ T cells, M0 and M2 macrophages, and activated mast cells were measured. Results: Increased M2 macrophage score [HR, 6.30; 95% confidence interval (CI), 3.0–12.15] and TGFβ signature expression (HR, 1.35; 95% CI, 1.05–1.77) were associated with shorter OS. Increased scores of plasma cells (HR, 0.55; 95% CI, 0.38–0.87) and activated memory CD4+ T cells (HR, 0.34; 95% CI, 0.16–0.65) were associated with longer OS. Using optimal cutoffs from these four features, patients were categorized as having either 4, 3, 2, or 0–1 beneficial features associated with longer OS, and the median (95% CI) OS decreased from 42.5 (35.8–47.8) to 31.0 (28.8–34.4), 25.2 (20.6–27.9), and 17.7 (13.5–20.4) months respectively (P = 3.48e–11). Conclusions: New immune features can be further evaluated to improve patient response. They provide the rationale for more effective immunotherapy strategies.
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Symonds, Lynn , Carter, Kelly , Innocenti, Federico , Bosch, Linda J.W. , Meijer, Gerrit A , Carvalho, Beatriz , Zemla, Tyler J, Carter, Kelly , Meijer, Gerrit A , Yu, Ming , Zhang, Yuhong , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Grady, William M. , Cohen, Stacey A.

Mayo Clinic

Epigenetics | April 12, 2022 | Volume: 17 | Issue: 12 | Pages: 1715-1725

10.1080/15592294.2022.2058225 | PMID 35412430 Get It

Transcriptional landscape of human microglia implicates age, sex, and APOE‐related immunometabolic pathway perturbations
Patel, Tulsi , Carnwath, Troy , Wang, Xue , Allen, Mariet , Lincoln, Sarah, Lewis‐Tuffin, Laura J. , Quicksall, Zachary , Lin, Shu, Tutor‐New, Frederick Q, Ho, Charlotte C.G. , Min, Yuhao , Malphrus, Kimberly G., Nguyen, Thuy , Martin, Elizabeth, Al‐kharboosh, Rawan , Chaichana, Kaisorn L. , Wharen, Robert E. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Ertekin‐Taner, Nilüfer , Carnwath, Troy P, Lincoln, Sarah J, Quicksall, Zachary S, Garcia, César A. , Alkharboosh, Rawan M, Chaichana, Kaisorn, Wharen, Robert, Ertekin-Taner, Nilüfer , Guerrero-Cazares, Hugo , Grewal, Sanjeet S.

Mayo Clinic

Aging Cell | April 7, 2022 | Volume: 21 | Issue: 5 | Pages: No page available

10.1111/acel.13606 | PMID 35388616 Get It

AbstractMicroglia have fundamental roles in health and disease; however, effects of age, sex, and genetic factors on human microglia have not been fully explored. We applied bulk and single‐cell approaches to comprehensively characterize human microglia transcriptomes and their associations with age, sex, and APOE. We identified a novel microglial signature, characterized its expression in bulk tissue and single‐cell microglia transcriptomes. We discovered microglial co‐expression network modules associated with age, sex, and APOE‐ε4 that are enriched for lipid and carbohydrate metabolism genes. Integrated analyses of modules with single‐cell transcriptomes revealed significant overlap between age‐associated module genes and both pro‐inflammatory and disease‐associated microglial clusters. These modules and clusters harbor known neurodegenerative disease genes including APOE, PLCG2, and BIN1. Meta‐analyses with published bulk and single‐cell microglial datasets further supported our findings. Thus, these data represent a well‐characterized human microglial transcriptome resource and highlight age, sex, and APOE‐related microglial immunometabolism perturbations with potential relevance in neurodegeneration.